Zymenex sells clinical candidate Metazym to Shire for EUR 85.6 Million
Zymenex A/S has achieved successful early clinical development of a therapeutic candidate Metazym against the rare, lethal and genetically caused, disease metachromatic leukodystrophy, MLD, which most often affects children at a very young age. This has now resulted in a sale of the therapeutic project to the global specialty biopharmaceutical company Shire plc.
Shire delivers EUR 85.6 Million to Zymenex in an upfront payment for global rights to the Metazym clinical candidate, which has been through clinical phase 1 and is currently in phase 2 in Denmark with European patients. Zymenex also receives EUR 1 Million for transitional services.